Subsequent studies using various EGFR TKIs similarly demonstrated higher ORR and longer PFS compared to platinum-based doublet chemotherapy both in recurrent metastatic lung adenocarcinoma and in frontline treatment of lung adenocarcinoma patients with sensitizing EGFR mutations (in this review we will be using the term lung adenocarcinoma to refer to non-small cell lung cancer with adenocarcinoma histology) [10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26]. Here, EGFR is linked to non-small cell lung carcinoma.